Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Current Investments (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Cash & Current Investments readings, the most recent being $10.6 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 15.07% to $10.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was $10.6 million, a 15.07% decrease, with the full-year FY2025 number at $10.9 million, down 14.84% from a year prior.
  • Cash & Current Investments hit $10.6 million in Q1 2026 for Pharma-Bio Serv, down from $10.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $15.9 million in Q1 2024 to a low of $10.4 million in Q2 2025.
  • Median Cash & Current Investments over the past 5 years was $13.5 million (2024), compared with a mean of $13.3 million.
  • Biggest five-year swings in Cash & Current Investments: rose 3.56% in 2023 and later dropped 22.75% in 2025.
  • Pharma-Bio Serv's Cash & Current Investments stood at $14.5 million in 2022, then increased by 3.56% to $15.0 million in 2023, then fell by 14.9% to $12.7 million in 2024, then dropped by 14.84% to $10.9 million in 2025, then fell by 2.71% to $10.6 million in 2026.
  • The last three reported values for Cash & Current Investments were $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $10.7 million (Q3 2025) per Business Quant data.